Exscientia plc (EXAI)
NASDAQ (NGS) 
Summary
EXAI Chart
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq: EXAI) ceased trading and will be delisted from Nasdaq.
Recursion and Exscientia Shareholders Approve the Proposed Combination
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia
Exscientia plc (EXAI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Exscientia plc ever had a stock split?
Exscientia plc Profile
| Biotechnology Industry | Healthcare Sector | Dr. David Hallett Ph.D. CEO | NASDAQ (NGS) Exchange | US30223G1022 ISIN |
| US Country | 483 Employees | - Last Dividend | - Last Split | 1 Oct 2021 IPO Date |
Overview
Exscientia plc is an innovative Pharma-tech entity distinguished by its use of artificial intelligence (AI) to spearhead the creation of novel medications. Specifically targeting diseases that presently lack adequate treatments, this company endeavors to meet these significant unmet patient needs through advanced AI-driven methodologies. Since its establishment in 2012, Exscientia has been at the forefront of integrating AI into the pharmaceutical development process, positioning itself as a pioneering force in the field. Headquartered in Oxford, the United Kingdom, the company has forged valuable collaboration agreements with industry giants and institutions such as Merck KGaA, Bristol Myers Squibb, Sanofi, the Bill & Melinda Gates Foundation, Charité – Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics, demonstrating its esteemed position in the sector and its commitment to addressing critical health challenges through innovative partnerships.
Products and Services
Exscientia is actively involved in the development of a diverse portfolio of therapeutic candidates across various stages of the drug development process, including:
- GTAEXS617 (CDK7 Inhibitor): Positioned as the company's leading product contender, this molecule is currently engaging in a Phase 1/2 trial. Its development is geared towards managing potential toxicities related to CDK7, while also fine-tuning pharmacokinetics to enhance on-target efficacy, showing promise for diseases that could benefit from CDK7 inhibition.
- EXS4318 (PKC-theta Inhibitor): This compound is under Phase 1 clinical investigation for its potential in treating inflammation and immunology-related conditions. By inhibiting PKC-theta, EXS4318 represents a strategic approach to modulating immune responses in various diseases.
- EXS74539 (LSD1 Inhibitor): Currently in preclinical studies, EXS74539 targets LSD1, a therapeutic approach for SCLC (Small Cell Lung Cancer), AML (Acute Myeloid Leukemia), and potentially other indications. Its development underscores Exscientia’s commitment to exploring solutions for challenging cancers.
- EXS73565 (MALT1 Inhibitor): This molecule, also in the preclinical study phase, is being explored for its potential in treating multiple hematology indications through the inhibition of MALT1, highlighting Exscientia's efforts in addressing hematological malignancies.
- DSP-0038: Undergoing Phase 1 studies, DSP-0038 is part of Exscientia’s pipeline exploring new frontiers in therapeutic development, reflecting the company’s dedication to innovation in drug discovery and development.
Contact Information
